Odense University Hospital

THURSDAY, Oct. 30, 2025 -- Two mechanisms of structural and functional retinal impairment based on papilledema severity have been identified among patients with idiopathic intracranial hypertension (IIH), according to a study published online Oct. 29 in Neurology . Laleh D. Molander, M.D., from Odense University Hospital in Denmark, and colleagues conducted a prospective cohort study at two tertiary headache centers from January 2018 to September 2022, including 154 adult patients with IIH to map patterns of structural and functional retinal damage according to papilledema severity. The researchers identified two mechanisms of structural and functional retinal damage according to papilledema severity. The first was impairment of the retinal nerve fiber layer, with increasing papilledema severity paralleled by increasing atrophy of the retinal nerve fiber layer and the ganglion cell layer, yielding peripheral scotomata, which did not affect visual acuity. The second mechanism was macular impairment, with persisting reduction of visual acuity resulting from grade 4 papilledema combined with macular edema, macular exudate, or disorganization of the inner retinal layer. A score was proposed to predict visual outcome using modified desirability of outcome ranking. There was a correlation for the score with papilledema severity and disorganization of the inner retinal layer, but no correlation with lumbar puncture opening pressure, neurofilament light chain, or magnetic resonance imaging characteristics associated with IIH. "This score needs to be validated by external groups before it can be considered ready for use, but we identified the severity of papilledema and the disorganization of the inner layer of the retina as major predictors for who will have persistent vision problems," coauthor Dagmar Beier, M.D., from the University of Southern Denmark, said in a statement. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required)

STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of the South Denmark Region, has placed an order for RayStation®*. The radiotherapy center at OUH is known for being at the forefront of automated solutions to provide high-quality care in an efficient way, including the ability to automatically generate treatment plans. With the introduction of RayStation, the clinic is now taking the next step by further developing automation to cover all aspects of the treatment planning process-from initial planning to finalized treatment plans. RayStation was chosen after an extensive evaluation of the market, where the decisive factor was to find a system that would enable OUH to continue developing new automated methods. RaySearch has had a strong focus on automation for a long time. RayStation offers several approaches for automated planning, both using machine learning techniques but also more conventional automated planning algorithms. In the upcoming version of RayStation, a new algorithm for automated optimization, which is still under development and led by Memorial Sloan Kettering Cancer Center in the US, will be included. The objective of the implementation project at Odense's radiotherapy center is to analyze the advantages of different auto-planning approaches and to clinically apply the approach that is best suited for each tumor site. Henrik Robenhagen Jensen, Chief Physicist, Odense University Hospital: "Odense University Hospital has long been dedicated to enhancing the quality of treatment planning, with a strong research focus on improving outcomes for cancer patients through state-of-the-art radiotherapy technologies. We are excited to begin our collaboration with RaySearch, which we see as a significant step forward. This partnership holds great promise for advancing automated treatment planning, with a clear emphasis on quality, efficiency, and the optimal use of clinical resources." Johan Löf, founder and CEO, RaySearch: "We have long been committed to increasing the degree of automation in RayStation. We are therefore particularly pleased that Odense University Hospital has chosen RayStation primarily based on this functionality. I am convinced that we will meet the center's requirements for automation and look forward to their feedback and a fruitful cooperation." The order value is DKK 10.5 million (approximately SEK 15.4 million), excluding service contract, of which the majority will be recognized as revenue in the first quarter of 2025. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected]  Learn more about us on: LinkedIn YouTube This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, Jan. 14, 2025 -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes , according to a study published online Dec. 18 in the International Journal of Retina and Vitreous . Jakob Grauslund, D.M.Sci., Ph.D., M.D., from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes. The analysis included 424,152 individuals (2018 to 2024) exposed (106,454 individuals) or not exposed (317,698 individuals) to once-weekly semaglutide. The researchers found that semaglutide exposure was significantly associated with a higher incidence rate (0.228 versus 0.093 per 1,000 person-years) and independently predicted a higher risk for upcoming NAION (hazard ratio, 2.19), even when accounting for multiple other factors. Of the 67 persons exposed to semaglutide who developed NAION, there was a median time from first prescription to event of 22.2 months (interquartile range, 10.2 to 37.8 months). "During five years of observation of all persons with type 2 diabetes in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION," the authors write. "Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.